INT192951

Context Info Confidence 0.38 First Reported 2006 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 15 Total Number 15 Disease Relevance 6.38 Pain Relevance 3.50

nucleus (AES)

Anatomy Link Frequency digits 1 AES (Homo sapiens)

Pain Link Frequency Relevance Heat Onset of action 3 99.88 Pain 188 99.76 cINOD 78 99.60 depression 3 99.54 Infliximab 36 97.84 nud 9 96.64 Pain management 4 96.16 Adalimumab 108 94.52 tolerance 4 93.76 Arthritis 3 92.36

Disease Link Frequency Relevance Heat Low Back Pain 20 99.76 Depression 3 99.54 Recurrence 17 99.42 Pain 186 98.88 Infection 73 97.80 Dyspepsia 9 96.64 Reprotox - General 1 6 94.04 Fecal Incontinence 65 93.36 Arthritis 3 92.36 Headache 75 91.36

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The greatest reduction in the number of GI AEs was seen in those subjects who remained on a dose of 20 mg taspoglutide throughout the study.

Negative_regulation (reduction) of AEs

1) Confidence 0.38 Published 2010 Journal Diabetic Medicine Section Body Doc Link PMC2948428 Disease Relevance 0.39 Pain Relevance 0.13

For migraineurs, the most important attributes of acute treatments are complete pain relief, lack of recurrence, rapid onset of action, and absence of AEs.

Negative_regulation (absence) of AEs associated with pain, onset of action and recurrence

2) Confidence 0.37 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656322 Disease Relevance 1.31 Pain Relevance 1.12

Reducing these nuisance AEs can lead to increased tolerability, compliance and patient satisfaction.

Negative_regulation (Reducing) of AEs

3) Confidence 0.37 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2984542 Disease Relevance 0.25 Pain Relevance 0.99

Recommended supportive care measures for managing AEs associated with bisphosphonate therapy are presented in Table 1.2,25,26 Quality of life

Negative_regulation (presented) of AEs

4) Confidence 0.34 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC3003608 Disease Relevance 0.58 Pain Relevance 0.16

8 fluid oz (237 mL) water after an overnight fast and not reclining, eating, or drinking for 30–60 minutes after dosing) reduces UGI AEs and enhances absorption.

Negative_regulation (reduces) of AEs

5) Confidence 0.34 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682394 Disease Relevance 0.26 Pain Relevance 0.31

He focused on other issues that could be determinant for patients in the long term, such as Progression in Adulthood (PiA), Breathing Function (BF) (in terms of survival), function in life (marrying, child-bearing, employment, depression, Back Pain [BP], Dis, Aes, neurological impairment).

Negative_regulation (impairment) of Aes associated with low back pain, pain and depression

6) Confidence 0.33 Published 2006 Journal Scoliosis Section Body Doc Link PMC1475888 Disease Relevance 0.42 Pain Relevance 0.15

The highest number of AEs occurred during the first 26 weeks of treatment with infliximab (Figure 2a).

Negative_regulation (number) of AEs associated with infliximab

7) Confidence 0.28 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911915 Disease Relevance 0.40 Pain Relevance 0.28

A number of the AEs related to treatment were indicative of perioperative infection which is not unexpected with treatments procedures in the anorectal region [53].

Negative_regulation (number) of AEs associated with infection

8) Confidence 0.25 Published 2010 Journal Gastroenterology Research and Practice Section Body Doc Link PMC3017894 Disease Relevance 0.60 Pain Relevance 0

Similarly, during 4 years of dutasteride treatment there was a trend towards a reduction in the rate of newly reported sexual AEs over time (51).

Negative_regulation (reduction) of AEs

9) Confidence 0.20 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.59 Pain Relevance 0

QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was significantly associated with the perception of health status, presence of adverse events (AEs) and number of reported AEs (P < 0.0001).

Negative_regulation (number) of AEs

10) Confidence 0.20 Published 2010 Journal Patient Prefer Adherence Section Abstract Doc Link PMC2875721 Disease Relevance 0.51 Pain Relevance 0

However, source data verification of 10% of patients did not suggest that a significant number of AEs were missed, with a similar occurrence of events reported for patients with different end digits of their patient number (Chi-squared test, p = 0.8).

Negative_regulation (number) of AEs in digits

11) Confidence 0.13 Published 2009 Journal Patient Saf Surg Section Body Doc Link PMC2711964 Disease Relevance 0.13 Pain Relevance 0

The number of AEs that occurred in the 40 and 80 mg groups were statistically significantly greater compared with the placebo group (P < 0.05 for both groups) (Table 4).

Negative_regulation (number) of AEs

12) Confidence 0.04 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.15 Pain Relevance 0.18

Exact Jonckheere–Terpstra (J-T) tests were performed to examine dose-response relationships for adverse events, according to dose of AMA1-C1 vaccine (control, low dose, and high dose) for each category of AE and total number of AEs.

Negative_regulation (number) of AEs

13) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2216433 Disease Relevance 0.08 Pain Relevance 0

Differences between adjuvant or dose groups were analyzed by Fisher's exact test for safety and reactogenicity data (numbers of AEs).

Negative_regulation (numbers) of AEs

14) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2749339 Disease Relevance 0 Pain Relevance 0.03

Unsolicited local and general AEs were monitored up to 30 d after injection in diary cards, but had to be reported anytime during the whole trial at each visit.

Negative_regulation (reported) of AEs

15) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2749339 Disease Relevance 0.72 Pain Relevance 0.16

General Comments

This test has worked.